{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:22:45Z","timestamp":1788340965618,"version":"build-2803163510"},"reference-count":343,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, I.P.","award":["UID\/06397\/2025"],"award-info":[{"award-number":["UID\/06397\/2025"]}]},{"award":["UID\/06397\/2025"],"award-info":[{"award-number":["UID\/06397\/2025"]}],"id":[{"id":"https:\/\/ror.org\/00snfqn58","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Interindividual pharmacokinetic (PK) variability remains a daunting challenge for effective and safe drug therapy. Despite the widespread use of direct oral anticoagulants (DOACs) and calcium channel blockers (CCBs), a substantial number of adverse drug reactions have been reported for both classes. Herein, this study aimed to assess and analyze the PK variability of DOACs and CCBs across diverse clinical and demographic profiles under both single- and multiple-dose conditions. Methods: A PubMed search identified clinical PK studies reporting maximum plasma concentration (Cmax) and\/or area under the concentration-time curve (AUC). The coefficient of variation (CV%) was calculated and used as a measure of PK variability. A CV% &lt; 40% indicated low-to-moderate variability, and a CV% &gt; 40% was defined as high variability. Results: A total of 264 studies were included following systematic screening, and the dataset was further characterized according to population features and clinical context. Among DOACs, edoxaban exhibited the lowest PK variability, whereas dabigatran showed the highest. CCBs demonstrated a broad variability spectrum, ranging from predictable agents (amlodipine and felodipine) to highly variable compounds (nisoldipine, isradipine, nimodipine, diltiazem, and verapamil). Studies evaluating drug\u2013drug interactions, ethnicity, and specific drug-related factors were associated with increased PK variability. Conclusions: These findings suggest that fixed-dose strategies may not be universally appropriate for DOACs and CCBs, particularly in high-risk subgroups where altered exposure may lead to sub- or supratherapeutic concentrations and compromise clinical outcomes. Therefore, clinicians should avoid evaluating individual risk factors in isolation and instead consider the patient\u2019s complete profile when selecting and adjusting pharmacotherapy.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091103","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:56:01Z","timestamp":1788339361000},"page":"1103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Variability of Direct Oral Anticoagulants and Calcium Channel Blockers: A Comparative Analysis of Exposure Data from Clinical Studies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4957","authenticated-orcid":false,"given":"Lara","family":"Marques","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/138920007779816002","article-title":"Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy","volume":"8","author":"Lin","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e70591","DOI":"10.1111\/cts.70591","article-title":"Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics-Based Biomarkers","volume":"19","author":"Prasad","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mpaic.2021.10.014","article-title":"Pharmacokinetic Variation","volume":"23","author":"Eusuf","year":"2022","journal-title":"Anaesth. Intensive Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.2714","article-title":"Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics","volume":"113","author":"Thompson","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Miceli, G., Ciaccio, A.M., and Tuttolomondo, A. (2025). Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092914"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Heestermans, M., Poenou, G., Hamzeh-Cognasse, H., Cognasse, F., and Bertoletti, L. (2022). Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells, 11.","DOI":"10.3390\/cells11203214"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Morgovan, C., Dobrea, C.M., Chis, A.A., Juncan, A.M., Arseniu, A.M., Rus, L.L., Gligor, F.G., Ardelean, S.A., Stoicescu, L., and Ghibu, S. (2023). A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030455"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.21037\/jtd.2018.03.95","article-title":"Recent Progress and Market Analysis of Anticoagulant Drugs","volume":"10","author":"Fan","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"McRae, H.L., Militello, L., and Refaai, M.A. (2021). Updates in Anticoagulation Therapy Monitoring. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030262"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12138","article-title":"Advantages and Limitations of the New Anticoagulants","volume":"275","author":"Schulman","year":"2014","journal-title":"J. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K Antagonists: Relative Strengths and Weaknesses vs. Direct Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1113-0655","article-title":"Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature","volume":"40","author":"Alberio","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Moudallel, S., Steurbaut, S., Cornu, P., and Dupont, A. (2018). Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01220"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1055\/s-0041-1731777","article-title":"The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation","volume":"05","author":"Fay","year":"2021","journal-title":"TH Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1002\/prp2.1235","article-title":"Risks of Oral Anticoagulants: Analysis of Adverse Drug Reactions Reported to the Portuguese National Pharmacovigilance System","volume":"12","author":"Martins","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_17","unstructured":"European Medicines Agency (2026, June 22). EudraVigilance\u2014European Database of Suspected Adverse Drug Reaction Reports. Available online: https:\/\/www.adrreports.eu\/."},{"key":"ref_18","first-page":"1","article-title":"Factors Influencing Hepatic Metabolism of Antihypertensive Drugs: Impact on Clinical Response","volume":"15","author":"Bertera","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Eraky, A.M., Mokhtar, Y., Grabau, G., Khan, A., Acharya, A., Gadd, N., Jarosz, M., and Premkumar, A. (2026). Calcium Channel Blockers in Critical Care Medicine: Current Clinical Applications and Future Investigational Perspectives. Med. Sci., 14.","DOI":"10.3390\/medsci14020213"},{"key":"ref_20","first-page":"CD003654","article-title":"Calcium Channel Blockers versus Other Classes of Drugs for Hypertension","volume":"2022","author":"Zhu","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/JMDH.S374887","article-title":"Calcium Channel Blocker Toxicity: A Practical Approach","volume":"15","author":"Alshaya","year":"2022","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"576249","DOI":"10.2147\/DHPS.S576249","article-title":"Long-Term Safety and Effectiveness of Calcium Channel Blockers in Hypertension: A Systematic Review","volume":"18","author":"Aisyah","year":"2026","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and Mortality in Patients Randomised to Double-Blind Treatment with a Long-Acting Calcium-Channel Blocker or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000168289","article-title":"Long-Term Effects of Enalapril and Nicardipine on Urinary Albumin Excretion in Patients with Chronic Renal Insufficiency: A 1-Year Follow-Up","volume":"11","author":"Bianchi","year":"1991","journal-title":"Am. J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/CIA.S60669","article-title":"Long-Term Effects of Antihypertensive Medications on Bone Mineral Density in Men Older than 55 Years","volume":"9","author":"Agacayak","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/15563650.2025.2571299","article-title":"2024 Annual Report of the National Poison Data System\u00ae (NPDS) from America\u2019s Poison Centers\u00ae: 42nd Annual Report","volume":"63","author":"Beuhler","year":"2025","journal-title":"Clin. Toxicol."},{"key":"ref_29","first-page":"III3-6","article-title":"Amlodipine: An Overview of Its Pharmacodynamic and Pharmacokinetic Properties","volume":"17","year":"1994","journal-title":"Clin. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00228-014-1716-8","article-title":"Evaluation of Felodipine as a Potential Perpetrator of Pharmacokinetic Drug-Drug Interactions","volume":"70","author":"Snyder","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_31","first-page":"336","article-title":"Bioavailability of Nifedipine from Different Oral Dosage Forms in Healthy Volunteers","volume":"44","author":"Olinic","year":"1989","journal-title":"Pharmazie"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1248\/bpb.28.882","article-title":"Inhibitory Effects of Nicardipine to Cytochrome P450 (CYP) in Human Liver Microsomes","volume":"28","author":"Nakamura","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2133\/dmpk.17.427","article-title":"Species Difference in Nisoldipine Oxidation Activity in the Small Intestine","volume":"17","author":"Komura","year":"2002","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2165\/00003495-199549040-00009","article-title":"Isradipine","volume":"49","author":"Brogden","year":"1995","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00610053","article-title":"Pharmacokinetics of Diltiazem after Intravenous and Oral Administration","volume":"24","author":"Hermann","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF00168924","article-title":"Cytochromes of the P450 2C Subfamily Are the Major Enzymes Involved in the O-Demethylation of Verapamil in Humans","volume":"353","author":"Busse","year":"1995","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bcp.16258","article-title":"Calcium Channel Blocker Overdose: Not All the Same Toxicity","volume":"91","author":"Isbister","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/cpdd.990","article-title":"Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration","volume":"10","author":"Frost","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_39","first-page":"153","article-title":"Evaluation of the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban in Healthy Japanese and Caucasian Subjects","volume":"10","author":"Frost","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-014-0228-0","article-title":"Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban","volume":"54","author":"Frost","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/cts.13284","article-title":"Pharmacokinetics of Apixaban and Tacrolimus or Cyclosporine in Kidney and Lung Transplant Recipients","volume":"15","author":"Mansell","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_42","first-page":"177","article-title":"Single- and Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Healthy Chinese Subjects","volume":"5","author":"Frost","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"ref_43","first-page":"19","article-title":"The Effect of Apixaban on the Pharmacokinetics of Digoxin and Atenolol in Healthy Subjects","volume":"9","author":"Frost","year":"2017","journal-title":"Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R D"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CP204299","article-title":"Pharmacokinetics, Safety, and Bioequivalence of Apixaban Tablets in Healthy Chinese Subjects under Fasting and Fed Conditions","volume":"61","author":"Luo","year":"2023","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an Oral, Direct Factor Xa Inhibitor: Single Dose Safety, Pharmacokinetics, Pharmacodynamics and Food Effect in Healthy Subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects with End-stage Renal Disease on Hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/jcph.1097","article-title":"Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects","volume":"58","author":"Byon","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.soard.2021.12.023","article-title":"The APB Study: Apixaban Pharmacokinetics in Bariatric Patients before to 1 Year after Vertical Sleeve Gastrectomy or Roux-En-Y Gastric Bypass","volume":"18","author":"Steele","year":"2022","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.xkme.2023.100646","article-title":"Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients","volume":"5","author":"Fung","year":"2023","journal-title":"Kidney Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of Apixaban, a Factor Xa Inhibitor, in Healthy Subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/jth.13801","article-title":"Dissociation between the Pharmacokinetics and Pharmacodynamics of Once-daily Rivaroxaban and Twice-daily Apixaban: A Randomized Crossover Study","volume":"15","author":"Kreutz","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e13257","DOI":"10.1590\/1414-431x2024e13257","article-title":"ABCG2 Polymorphism and Rivaroxaban Pharmacokinetics in Healthy Individuals after a Single Dose","volume":"57","author":"Francisco","year":"2024","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e13853","DOI":"10.1111\/cts.13853","article-title":"Pharmacokinetics of Single-dose Rivaroxaban under Fed State in Obese vs. Non-obese Subjects: An Open-label Controlled Clinical Trial (RIVOBESE-PK)","volume":"17","author":"Alalawneh","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-Escalation Study of the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Elderly Subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/FJC.0b013e31822f6c2b","article-title":"Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban","volume":"58","author":"Moore","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.2009.03390.x","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Single\/Multiple Doses of the Oral, Direct Factor Xa Inhibitor Rivaroxaban in Healthy Chinese Subjects","volume":"68","author":"Zhao","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jcph.352","article-title":"An Open-label Study to Estimate the Effect of Steady-state Erythromycin on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban in Subjects with Renal Impairment and Normal Renal Function","volume":"54","author":"Moore","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cpdd.1092","article-title":"A Single-blind, Randomized, Single-dose, Two-sequence, Two-period, Crossover Study to Assess the Bioequivalence between Two Oral Tablet Formulations of Rivaroxaban 20 Mg in Healthy Mexican Volunteers","volume":"11","author":"Moquete","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clinthera.2024.02.009","article-title":"The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study","volume":"46","author":"Liu","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1111\/bcp.13757","article-title":"Rivaroxaban and Macitentan Can Be Coadministered without Dose Adjustment but the Combination of Rivaroxaban and St John\u2019s Wort Should Be Avoided","volume":"84","author":"Huppertz","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e70439","DOI":"10.1111\/cts.70439","article-title":"Assessment of Pharmacokinetics and Food Effect of AD-109, a Novel Formulation of Rivaroxaban 18\u2009Mg","volume":"18","author":"Ryu","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban\u2014An Oral, Direct Factor Xa Inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual Variability in Dabigatran and Rivaroxaban Exposure: Contribution of ABCB1 Genetic Polymorphisms and Interaction with Clarithromycin","volume":"15","author":"Delavenne","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cpdd.1342","article-title":"Bioequivalence Study of Capsules versus Film Tablets Containing Rivaroxaban in Healthy Caucasian Subjects under Fasting and Fed Conditions","volume":"13","author":"Inal","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939)\u2014An Oral, Direct Factor Xa Inhibitor\u2014Has No Clinically Relevant Interaction with Naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1177\/030006051204000508","article-title":"Absence of Clinically Relevant Interactions between Rivaroxaban\u2014An Oral, Direct Factor Xa Inhibitor\u2014And Digoxin or Atorvastatin in Healthy Subjects","volume":"40","author":"Kubitza","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.soard.2018.08.025","article-title":"The Effect of Bariatric Surgery on the Direct Oral Anticoagulant Rivaroxaban: The Extension Study","volume":"14","author":"Nett","year":"2018","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/00498254.2025.2522731","article-title":"Effects of ABCG2 421C > A Genetic Polymorphism on the Pharmacokinetics of Rivaroxaban in Healthy Chinese Subjects","volume":"55","author":"Guo","year":"2025","journal-title":"Xenobiotica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpdd.742","article-title":"Bioequivalence Study of 2 Formulations of Rivaroxaban, a Narrow-Therapeutic-Index Drug, in Healthy Chinese Subjects Under Fasting and Fed Conditions","volume":"9","author":"Ding","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.12599","article-title":"Comparison of Three-factor and Four-factor Prothrombin Complex Concentrates Regarding Reversal of the Anticoagulant Effects of Rivaroxaban in Healthy Volunteers","volume":"12","author":"Levi","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.13934","article-title":"Perpetrator Effects of Ciclosporin (P-glycoprotein Inhibitor) and Its Combination with Fluconazole (CYP3A Inhibitor) on the Pharmacokinetics of Rivaroxaban in Healthy Volunteers","volume":"85","author":"Brings","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40292-019-00342-4","article-title":"Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery","volume":"26","author":"Sychev","year":"2019","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.jtha.2024.06.024","article-title":"Full-Dose Rivaroxaban in Patients with a History of Bariatric Surgery: Bridging the Knowledge Gap through a Phase 1 Study","volume":"22","author":"Leven","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"118997","DOI":"10.1016\/j.jep.2024.118997","article-title":"Impact of Banhabaekchulcheonmatang (Banxia Baizhu Tianma Tang) and Hwangryeonhaedoktang (Huang Lian Jie Du Tang) on Edoxaban: Herb-Drug Interaction Study in Healthy Subjects","volume":"337","author":"Cho","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10557-023-07443-2","article-title":"Effect of Clarithromycin, a Strong CYP3A and P-Glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach","volume":"38","author":"Lenard","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40261-015-0298-2","article-title":"The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults","volume":"35","author":"Mendell","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban Drug\u2013Drug Interactions with Ketoconazole, Erythromycin, and Cyclosporine","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/00498254.2016.1207825","article-title":"A Single-Dose Study Investigating the Pharmacokinetics and Pharmacodynamics of Edoxaban at 30\u201390\u2009Mg in Healthy Chinese Volunteers","volume":"47","author":"Chen","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt.3196","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single-Dose Study","volume":"116","author":"Zou","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/bcp.70369","article-title":"Effect of Enzalutamide on Anticoagulant Therapy with Edoxaban in Patients with Prostate Cancer","volume":"92","author":"Mehra","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2023.05.021","article-title":"Effect of the P-Glycoprotein Inhibitor Tamoxifen on Edoxaban Plasma Levels in Women with Breast Cancer","volume":"228","author":"Bosch","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/cpdd.1050","article-title":"Edoxaban Exposure in Patients with Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL\/min","volume":"11","author":"Yin","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The Pharmacokinetics, Pharmacodynamics and Tolerability of Dabigatran Etexilate, a New Oral Direct Thrombin Inhibitor, in Healthy Male Subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40261-023-01310-6","article-title":"Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects","volume":"43","author":"Dingemanse","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1111\/bcp.15835","article-title":"Effects of Nirmatrelvir\/Ritonavir on Midazolam and Dabigatran Pharmacokinetics in Healthy Participants","volume":"89","author":"Cox","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Rattanacheeworn, P., Kerr, S.J., Kittanamongkolchai, W., Townamchai, N., Udomkarnjananun, S., Praditpornsilpa, K., Thanusuwannasak, T., Udomnilobol, U., Jianmongkol, S., and Ongpipattanakul, B. (2021). Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.726669"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","article-title":"Effect of Bosutinib on the Absorption of Dabigatran Etexilate Mesylate, a P-Glycoprotein Substrate, in Healthy Subjects","volume":"73","author":"Hsyu","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral Bioavailability of Dabigatran Etexilate (Pradaxa\u00ae) after Co-medication with Verapamil in Healthy Subjects","volume":"75","author":"Sennewald","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the Oral Bioavailability of Dabigatran Etexilate after Co-medication with Rifampicin","volume":"74","author":"Sharma","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e70490","DOI":"10.1111\/cts.70490","article-title":"The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications","volume":"19","author":"Schmith","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cpt.1998","article-title":"A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment","volume":"109","author":"Tatosian","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10637-023-01378-z","article-title":"Assessment of the Potential of the MET Inhibitor Tepotinib to Affect the Pharmacokinetics of CYP3A4 and P-Gp Substrates","volume":"41","author":"Yalkinoglu","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Xie, Q., Li, Y., Liu, Z., Mu, G., Zhang, H., Zhou, S., Wang, Z., Wang, Z., Jiang, J., and Li, X. (2022). SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated with Dabigatran Metabolism in a Healthy Chinese Population. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.873031"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/jcph.1558","article-title":"Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate","volume":"60","author":"Monk","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_103","first-page":"477","article-title":"The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects","volume":"14","author":"Liu","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/jth.13847","article-title":"Phase IIa Study of Dabigatran Etexilate in Children with Venous Thrombosis: Pharmacokinetics, Safety, and Tolerability","volume":"15","author":"Halton","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00228-011-1205-2","article-title":"Switching from Enoxaparin to Dabigatran Etexilate: Pharmacokinetics, Pharmacodynamics, and Safety Profile","volume":"68","author":"Clemens","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yang, Z., Li, Q., Yu, D., Zhang, X., Wang, Y., Liu, S., Chen, L., Zhou, Y., Zeng, C., and Zeng, Y. (2025). A Single-Dose, Four-Cycle, Fully Repetitive Crossover Bioequivalence of Dabigatran Etexilate in Chinese. BMC Pharmacol. Toxicol., 26.","DOI":"10.1186\/s40360-025-00896-1"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1002\/bcp.70198","article-title":"Effect of Vepdegestrant, a PROTAC Oestrogen Receptor Degrader, on Dabigatran and Rosuvastatin Pharmacokinetics in Healthy Participants","volume":"91","author":"Yang","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s13318-020-00626-4","article-title":"Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects","volume":"45","author":"Duan","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rth2.12029","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Idarucizumab, a Specific Dabigatran Reversal Agent in Healthy Japanese Volunteers: A Randomized Study","volume":"1","author":"Yasaka","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF03256595","article-title":"Coadministration of Dabigatran Etexilate and Atorvastatin","volume":"9","author":"Stangier","year":"2009","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1074248418769167","article-title":"Pharmacokinetics\/Pharmacodynamics of Dabigatran 75 Mg Twice Daily in Patients with Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function","volume":"23","author":"Martin","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0091270010393342","article-title":"Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, with Coadministration of Digoxin","volume":"52","author":"Stangier","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1007\/s12325-020-01439-2","article-title":"Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study","volume":"37","author":"Wang","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2016.06.017","article-title":"An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate 150 mg Once Daily in Caucasian Patients with Moderate Renal Impairment Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery","volume":"144","author":"Eriksson","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00228-012-1304-8","article-title":"Pharmacokinetic and Pharmacodynamic Effects of Comedication of Clopidogrel and Dabigatran Etexilate in Healthy Male Volunteers","volume":"69","author":"Sennewald","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpdd.1472","article-title":"Phase 1 Evaluation of the Bioequivalence and Drug-Drug Interaction Potential of a Novel Fixed-Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine","volume":"13","author":"Lim","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0091270008322176","article-title":"Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed-Dose Combination","volume":"48","author":"Rohatagi","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0149-2918(04)90071-9","article-title":"Randomized, Open-Label, Two-Period Crossover Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Two Amlodipine Formulations in Healthy Adult Male Korean Subjects","volume":"26","author":"Park","year":"2004","journal-title":"Clin. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.clinthera.2006.11.008","article-title":"Pharmacokinetic and Pharmacodynamic Characteristics of a New S-Amlodipine Formulation in Healthy Korean Male Subjects: A Randomized, Open-Label, Two-Period, Comparative, Crossover Study","volume":"28","author":"Park","year":"2006","journal-title":"Clin. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2125.2006.02733.x","article-title":"Effect of ABCB1 (MDR1) Haplotypes Derived from G2677T\/C3435T on the Pharmacokinetics of Amlodipine in Healthy Subjects","volume":"63","author":"Kim","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/chir.20588","article-title":"Effect of Cytochrome P450 3A5*3 Genotype on the Stereoselective Pharmacokinetics of Amlodipine in Healthy Subjects","volume":"21","author":"Kim","year":"2009","journal-title":"Chirality"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2133\/dmpk.DMPK-12-RG-148","article-title":"Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine","volume":"28","author":"Zuo","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_123","first-page":"467","article-title":"Comparative Bioavailability Cf Two Amlodipine Formulation in Healthy Volunteers","volume":"57","author":"Setiawati","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1007\/s00210-024-03513-w","article-title":"A Single-Dose, Randomized, Crossover Bioequivalence Study of Levamlodipine Besilate Tablets in Healthy Subjects","volume":"398","author":"Deng","year":"2025","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/s41598-025-32576-9","article-title":"Pharmacokinetic and Bioequivalence of Two Formulations of Valsartan\/Amlodipine Tablet(I) in Healthy Chinese Volunteers: A Randomized, Three-Period, Partially Replicated Crossover Study","volume":"16","author":"Mei","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1074248417691135","article-title":"Evaluation of the Potential for Drug Interactions with Patiromer in Healthy Volunteers","volume":"22","author":"Lesko","year":"2017","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0091270006291031","article-title":"Bioavailability of Amlodipine Besylate\/Atorvastatin Calcium Combination Tablet","volume":"46","author":"Chung","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1007\/s12325-024-02869-y","article-title":"Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil\/Amlodipine\/Atorvastatin Versus Co-Administration of Individual Formulations in Healthy Participants","volume":"41","author":"Kim","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-003-0620-4","article-title":"Pharmacokinetics of Amlodipine in Hypertensive Patients Undergoing Haemodialysis","volume":"59","author":"Kungys","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5414\/CP202045","article-title":"Pharmacokinetic Comparison of Amlodipine Adipate\/Valsartan Fixed-Dose Combination with Amlodipine Besylate\/Valsartan Fixed-Dose Combination in Healthy Volunteers","volume":"53","author":"Nam","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5414\/CPP44641","article-title":"Comparative Pharmacokinetic and Pharmacodynamic Characteristics of Amlodipine Besylate and Amlodipine Nicotinate in Healthy Subjects","volume":"44","author":"Park","year":"2006","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Li, T., Liu, Y., Liu, S., Shi, P., Jiang, X., Tao, Y., Gao, X., Ma, Y., and Cao, Y. (2022). Bioequivalence Evaluation and Food Effect Assessment of Lisinopril\/Amlodipine Tablets in Healthy Chinese Subjects under Fasting and Fed Conditions. BMC Pharmacol. Toxicol., 23.","DOI":"10.1186\/s40360-022-00590-6"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpdd.214","article-title":"The Relative Bioavailability of 2 Prototype Fixed-dose Combination Formulations for Amlodipine and Rosuvastatin in Healthy White and Chinese Subjects","volume":"5","author":"Nwe","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.curtheres.2005.04.005","article-title":"Bioavailability Study of Fixed-Dose Tablet versus Capsule Formulation of Amlodipine plus Benazepril: A Randomized, Single-Dose, Two-Sequence, Two-Period, Open-Label, Crossover Study in Healthy Volunteers","volume":"66","author":"Chien","year":"2005","journal-title":"Curr. Ther. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40261-012-0026-0","article-title":"Pharmacokinetic and Pharmacodynamic Profiles of a Fixed-Dose Combination of Olmesartan Medoxomil and Amlodipine in Healthy Chinese Males and Females","volume":"32","author":"Chen","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e70024","DOI":"10.1002\/cpdd.70024","article-title":"Pharmacokinetic Interaction Among Amlodipine, Losartan, and Chlorthalidone after a Single Oral Administration in Healthy Male Subjects","volume":"15","author":"Moon","year":"2026","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/DDDT.S156492","article-title":"Pharmacokinetic and Bioequivalence Study of a Telmisartan\/S-Amlodipine Fixed-Dose Combination (CKD-828) Formulation and Coadministered Telmisartan and S-Amlodipine in Healthy Subjects","volume":"12","author":"Kang","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.clinthera.2017.05.355","article-title":"Bioequivalence Study of a New Fixed-Dose Combination Tablet Containing S-Amlodipine Nicotinate and Olmesartan Medoxomil in Healthy Korean Male Subjects","volume":"39","author":"Oh","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/00912709922011782","article-title":"The Pharmacokinetics of Extended-Release Formulations of Calcium Antagonists and of Amlodipine in Subjects with Different Gastrointestinal Transit Times","volume":"39","author":"Zimmermann","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"53","DOI":"10.12793\/tcp.2021.29.e5","article-title":"Pharmacokinetic Comparison between a Fixed-Dose Combination of Fimasartan\/Amlodipine\/Hydrochlorothiazide 60\/10\/25 mg and a Corresponding Loose Combination of Fimasartan\/Amlodipine 60\/25 Mg and Hydrochlorothiazide 25 Mg in Healthy Subjects","volume":"29","author":"Jung","year":"2021","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.2147\/DDDT.S82820","article-title":"Bioequivalence Evaluation of Two Amlodipine Salts, Besylate and Orotate, Each in a Fixed-Dose Combination with Olmesartan in Healthy Subjects","volume":"9","author":"Lee","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clinthera.2010.01.017","article-title":"Pharmacodynamic (Hemodynamic) and Pharmacokinetic Comparisons of S-Amlodipine Gentisate and Racemate Amlodipine Besylate in Healthy Korean Male Volunteers: Two Double-Blind, Randomized, Two-Period, Two-Treatment, Two-Sequence, Double-Dummy, Single-Dose Crossover Studies","volume":"32","author":"Kim","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12793\/tcp.2019.27.4.134","article-title":"Pharmacokinetic Comparison between Fixed-Dose Combination of Fimasartan\/Amlodipine 60\/10 mg and the Corresponding Loose Combination through Partial Replicated Crossover Study in Healthy Subjects","volume":"27","author":"Yang","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cpdd.727","article-title":"Pharmacokinetic and Safety Profiles of a Fixed-Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3-Period Replicate Crossover Study","volume":"9","author":"Kim","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40256-013-0051-2","article-title":"Pharmacokinetics, Tolerability, and Safety of the Single Oral Administration of AGSAV301 vs Exforge: A Randomized Crossover Study of Healthy Male Volunteers","volume":"14","author":"Choi","year":"2014","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","article-title":"The Pharmacokinetics of Amlodipine in Healthy Volunteers after Single Intravenous and Oral Doses and after 14 Repeated Oral Doses given Once Daily","volume":"22","author":"Faulkner","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.clinthera.2013.05.021","article-title":"Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study","volume":"35","author":"Kim","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-0031-1296632","article-title":"Pharmacokinetics and Bioequivalence Study of a Generic Amlodipine Tablet Formulation in Healthy Male Volunteers","volume":"57","author":"Sailer","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.clinthera.2019.08.020","article-title":"Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects","volume":"41","author":"Moon","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/DDDT.S498337","article-title":"Bioequivalence Study of Single-Pill Capsule Formulation of Amlodipine Plus Benazepril in Healthy Chinese Subjects Under Fasting and Fed Conditions","volume":"19","author":"Song","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e23228","DOI":"10.1002\/jcla.23228","article-title":"Evaluation of Pharmacokinetics and Safety with Bioequivalence of Amlodipine in Healthy Chinese Volunteers: Bioequivalence Study Findings","volume":"34","author":"Wang","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0033-1357143","article-title":"The Influence of Food on the Pharmacokinetics of Amlodipine and Losartan after Single-Dose of Its Compound Tablets in Healthy Chinese Subjects","volume":"64","author":"Lv","year":"2013","journal-title":"Drug Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.clinthera.2009.04.013","article-title":"Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of 10-Mg Amlodipine Besylate: An Open-Label, Single-Dose, Randomized, Two-Way Crossover Study in Healthy Chinese Male Volunteers","volume":"31","author":"Liu","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.2147\/DDDT.S113891","article-title":"Comparisons of the Pharmacokinetics and Tolerability of Fixed-Dose Combinations of Amlodipine Besylate\/Losartan and Amlodipine Camsylate\/Losartan in Healthy Subjects: A Randomized, Open-Label, Single-Dose, Two-Period, Two-Sequence Crossover Study","volume":"10","author":"Choi","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cpdd.1086","article-title":"Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions","volume":"11","author":"Li","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40268-024-00460-y","article-title":"Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-Administration of Four Individual Components in Healthy Participants","volume":"24","author":"Park","year":"2024","journal-title":"Drugs R D"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/DDDT.S485851","article-title":"Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan\/Amlodipine (80\/5 mg) in Healthy Chinese Subjects","volume":"19","author":"Tian","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/cpdd.1064","article-title":"Pharmacokinetics, Bioequivalence, and Safety Studies of Amlodipine Besylate in Healthy Subjects","volume":"11","author":"Chen","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.12793\/tcp.2020.28.e8","article-title":"Pharmacokinetics and Bioequivalence of Fixed-Dose Combination of Candesartan Cilexetil\/Amlodipine Besylate (16\/10 mg) versus Coadministration of Individual Formulations in Healthy Subjects","volume":"28","author":"Lee","year":"2020","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cpdd.963","article-title":"Pharmacokinetics of a Fixed-Dose Combination of Amlodipine\/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components","volume":"11","author":"Jeon","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/FJC.0b013e3181fc45bb","article-title":"Pharmacokinetic and Antihypertensive Profile of Amlodipine and Felodipine-ER in Younger Versus Older Patients with Hypertension","volume":"56","author":"Leenen","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1742-1241.2006.01164.x","article-title":"Lack of Pharmacokinetic Interactions of Aliskiren, a Novel Direct Renin Inhibitor for the Treatment of Hypertension, with the Antihypertensives Amlodipine, Valsartan, Hydrochlorothiazide (HCTZ) and Ramipril in Healthy Volunteers","volume":"60","author":"Vaidyanathan","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0091270007307880","article-title":"Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions with the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects","volume":"48","author":"He","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FJC.0b013e31821795d0","article-title":"Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, with Amlodipine in Healthy Volunteers","volume":"57","author":"Yi","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.clinthera.2012.05.010","article-title":"Pharmacokinetic Interaction of Telmisartan with S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers","volume":"34","author":"Noh","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clpt.2005.04.005","article-title":"Pharmacokinetic Interactions between Indinavir plus Ritonavir and Calcium Channel Blockers","volume":"78","author":"Glesby","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0091270010376963","article-title":"Evaluation of Pharmacokinetic Interactions Between Amlodipine, Valsartan, and Hydrochlorothiazide in Patients with Hypertension","volume":"51","author":"Bhad","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.clinthera.2015.06.009","article-title":"Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator\u2013Activated Receptor-\u03b3 Agonist, in Healthy Subjects","volume":"37","author":"Kim","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12325-019-00976-9","article-title":"Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers","volume":"36","author":"Seong","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpdd.787","article-title":"Safety of Candesartan, Amlodipine, and Atorvastatin in Combination: Interaction Study in Healthy Subjects","volume":"10","author":"Gundlach","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.2147\/DDDT.S465652","article-title":"Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe\/Rosuvastatin 10\/20 Mg and the Fixed-Dose Combination of Telmisartan\/Amlodipine 80\/5 mg in Healthy Subjects","volume":"18","author":"Ryu","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/009127000004001206","article-title":"Pharmacokinetics of Repeated Oral Doses of Amlodipine and Amlodipine plus Telmisartan in Healthy Volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2016.06.011","article-title":"Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-Label, Multiple-Dose, 2-Period Crossover Study","volume":"38","author":"Son","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00609197","article-title":"Pharmacokinetics of Amlodipine in Renal Impairment","volume":"36","author":"Doyle","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.2147\/DDDT.S210364","article-title":"Pharmacokinetic Interactions between Telmisartan\/Amlodipine and Rosuvastatin after Multiple Oral Administrations in Healthy Korean Male Subjects","volume":"13","author":"Moon","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/17425255.2019.1650913","article-title":"S-Amlodipine\u2013Bisoprolol Combination Therapy Caused Elevated Transaminases and Triglyceride Levels in Healthy Chinese Subjects: A Randomized Controlled, Open-Label, Multiple-Dose Pharmacokinetic Interaction Study","volume":"15","author":"Liu","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bcpt.13244","article-title":"Pharmacokinetic and Haemodynamic Interactions between Amlodipine and Losartan in Human Beings","volume":"125","author":"Park","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/DDDT.S348897","article-title":"Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers","volume":"16","author":"Kim","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpdd.324","article-title":"Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide","volume":"6","author":"Gillen","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00005344-199003000-00013","article-title":"Plasma Concentration\u2014Effect Relationships of Intravenous and Extended-Release Oral Felodipine in Hypertensive Patients","volume":"15","author":"Blychert","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00558072","article-title":"Pharmacokinetics of Felodipine in Patients with Liver Disease","volume":"36","author":"Edgar","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00558124","article-title":"Haemodynamic Effects and Pharmacokinetics of Felodipine at Rest and during Exercise in Hypertensive Patients Treated with Metoprolol or Atenolol","volume":"37","author":"Elmfeldt","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2796.1989.tb00072.x","article-title":"Effects of Felodipine on Plasma Digoxin Levels and Haemodynamics in Patients with Heart Failure","volume":"225","author":"Kirch","year":"1989","journal-title":"J. Intern. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0009-9236(97)90191-0","article-title":"Itraconazole Greatly Increases Plasma Concentrations and Effects of Felodipine","volume":"61","author":"Jalava","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002280050093","article-title":"Pharmacokinetic Interaction between Cyclosporine and the Dihydropyridine Calcium Antagonist Felodipine","volume":"50","author":"Madsen","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e034086","DOI":"10.1136\/bmjopen-2019-034086","article-title":"Severity of Coeliac Disease and Clinical Management Study When Using a CYP3A4 Metabolised Medication: A Phase I Pharmacokinetic Study","volume":"10","author":"Chretien","year":"2020","journal-title":"BMJ Open"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0009-9236(96)90163-0","article-title":"Erythromycin-Felodipine Interaction: Magnitude, Mechanism, and Comparison with Grapefruit Juice","volume":"60","author":"Bailey","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e00346","DOI":"10.1002\/prp2.346","article-title":"Coffee Inhibition of CYP 3A4 in Vitro Was Not Translated to a Grapefruit-like Pharmacokinetic Interaction Clinically","volume":"5","author":"Dresser","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_190","first-page":"1386","article-title":"Coffee\u2014Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study with Felodipine","volume":"29","author":"Bailey","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2125.1989.tb05336.x","article-title":"Pharmacokinetics of Felodipine in Patients with Impaired Renal Function","volume":"27","author":"Edgar","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mcp.2000.107524","article-title":"Grapefruit Juice\u2013Felodipine Interaction in the Elderly","volume":"68","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/bdd.2510080305","article-title":"Pharmacokinetic and Pharmacodynamic Studies of Felodipine in Healthy Subjects after Various Single, Oral and Intravenous Doses","volume":"8","author":"Edgar","year":"1987","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002280050263","article-title":"Effects of Grapefruit Juice Ingestion\u2014Pharmacokinetics and Haemodynamics of Intravenously and Orally Administered Felodipine in Healthy Men","volume":"52","author":"Lundahl","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jcpt.12505","article-title":"The Influence of CYP3A5*3 and BCRPC421A Genetic Polymorphisms on the Pharmacokinetics of Felodipine in Healthy Chinese Volunteers","volume":"42","author":"Xiang","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003495-198700343-00009","article-title":"Pharmacokinetics of Felodipine and Effect on Digoxin Plasma Levels in Patients with Heart Failure","volume":"34","author":"Rehnqvist","year":"1987","journal-title":"Drugs"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00228-004-0847-8","article-title":"Effect of Menthol on the Pharmacokinetics and Pharmacodynamics of Felodipine in Healthy Subjects","volume":"60","author":"Gelal","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2125.1988.tb05295.x","article-title":"Effect of Indomethacin on the Pharmacokinetics and Pharmacodynamics of Felodipine","volume":"26","author":"Hardy","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007691-199302000-00007","article-title":"Influence of Single and Repeated Doses of Oxcarbazepine on the Pharmacokinetic Profile of Felodipine","volume":"15","author":"Zaccara","year":"1993","journal-title":"Ther. Drug Monit."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2165\/00003088-198814060-00004","article-title":"Pharmacokinetics and Blood Pressure Effects of Felodipine in Elderly Hypertensive Patients","volume":"14","author":"Landahl","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s002280050424","article-title":"The Interaction Effect of Grapefruit Juice Is Maximal after the First Glass","volume":"54","author":"Lundahl","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"70752","DOI":"10.18632\/oncotarget.19984","article-title":"Pharmacokinetics and Drug-Drug Interaction between Enalapril, Enalaprilat and Felodipine Extended Release (ER) in Healthy Subjects","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2125.1991.tb03852.x","article-title":"A Population Study of the Pharmacokinetics of Felodipine","volume":"31","author":"Blychert","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/clpt.1985.89","article-title":"Nifedipine: Influence of Renal Function on Pharmacokinetic\/Hemodynamic Relationship","volume":"37","author":"Kleinbloesem","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00271372","article-title":"The Pharmacodynamics and Pharmacokinetics of the Combination of Nifedipine and Doxazosin","volume":"44","author":"Donnelly","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.1988.94","article-title":"Effect of Cimetidine or Ranitidine Administration on Nifedipine Pharmacokinetics and Pharmacodynamics","volume":"43","author":"Schwartz","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0928-0987(02)00008-8","article-title":"Formulation-Dependent Food Effects Demonstrated for Nifedipine Modified-Release Preparations Marketed in the European Union","volume":"15","author":"Schug","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1124\/dmd.112.046060","article-title":"The Effects on Metabolic Clearance When Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole","volume":"40","author":"Willis","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.1988.tb03306.x","article-title":"The Effect of Ageing on the Disposition of Nifedipine and Atenolol","volume":"25","author":"Scott","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cpdd.1396","article-title":"Comparative Bioequivalence and Food Effect of Two Formulations of 30-mg Nifedipine Controlled-Release Tablets in Healthy Chinese Adults","volume":"13","author":"Zhang","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_211","first-page":"1266","article-title":"Study on the Bioequivalence of an Oral Nifedipine Formulation and a Sustained Release Reference Preparation after Single Dose and Repeated Doses","volume":"45","author":"Martens","year":"1995","journal-title":"Arzneimittelforschung"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/j.1552-4604.1996.tb04211.x","article-title":"Lack of Effect of Orlistat on the Bioavailability of a Single Dose of Nifedipine Extended-Release Tablets (Procardia XL) in Healthy Volunteers","volume":"36","author":"Melia","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2125.1986.tb05211.x","article-title":"The Bioavailability and Pharmacokinetics of Slow Release Nifedipine during Chronic Dosing in Volunteers","volume":"21","author":"Debbas","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bdd.386","article-title":"Pharmacokinetics of Nifedipine in Taiwanese","volume":"25","author":"Chien","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2125.1987.tb03050.x","article-title":"Ranitidine and Cimetidine; Drug Interactions with Single Dose and Steady-state Nifedipine Administration","volume":"23","author":"Smith","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2125.2010.03729.x","article-title":"Effect of Single and Repeat Doses of Casopitant on the Pharmacokinetics of CYP450 3A4 Substrates Midazolam and Nifedipine","volume":"70","author":"Zamuner","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2147\/DDDT.S237301","article-title":"Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors","volume":"14","author":"Zhu","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00266355","article-title":"Influence of Single- and Multiple-Dose Omeprazole Treatment on Nifedipine Pharmacokinetics and Effects in Healthy Subjects","volume":"42","author":"Soons","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/a-1035-9212","article-title":"Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers","volume":"70","year":"2020","journal-title":"Drug Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpdd.1258","article-title":"Pharmacokinetics and Bioequivalence of 2 Nifedipine Controlled-Release Tablets: A Randomized, Single-Dose, 2-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions","volume":"12","author":"Xin","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00558229","article-title":"Total and Free Steady-State Plasma Levels and Pharmacokinetics of Nifedipine in Patients with Terminal Renal Failure","volume":"37","author":"Bortel","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1472-8206.1988.tb00618.x","article-title":"Pharmacokinetic Interaction Between Nifedipine and Propranolol","volume":"2","author":"Koren","year":"1988","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2796.1990.tb00168.x","article-title":"Nifedipine as an Antihypertensive Drug in Patients with Renal Failure\u2014Pharmacokinetics and Effects","volume":"227","author":"Anderson","year":"1990","journal-title":"J. Intern. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00637629","article-title":"Haemodynamic Effects of Combined Oral Nifedipine and Sublingual Nitroglycerin in Patients with Chronic Stable Angina","volume":"33","author":"Boje","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2125.1989.tb03551.x","article-title":"The Influence of Food on the Pharmacokinetics of \u2018Biphasic\u2019 Nifedipine at Steady State in Normal Subjects","volume":"28","author":"Rimoy","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2165\/00003495-199400481-00006","article-title":"Pharmacokinetic Profile of Nifedipine GITS in Hypertensive Patients with Chronic Renal Impairment","volume":"48","author":"Schneider","year":"1994","journal-title":"Drugs"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/bdd.2510150607","article-title":"Relative Bioavailability of Four Controlled-release Nifedipine Products","volume":"15","author":"Schall","year":"1994","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0032-1323590","article-title":"Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic","volume":"30","author":"Haas","year":"2012","journal-title":"Am. J. Perinatol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2125.1991.tb03943.x","article-title":"The Pharmacokinetics and Pharmacodynamics of Nifedipine at Steady State during Concomitant Administration of Cimetidine or High Dose Ranitidine","volume":"32","author":"Khan","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/j.1552-4604.1986.tb02954.x","article-title":"Pharmacokinetics and Pharmacodynamics of Nifedipine in Patients at Steady State","volume":"26","author":"Gutierrez","year":"1986","journal-title":"J. Clin. Pharmacol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0939-6411(03)00027-4","article-title":"Influence of Menthol and Pressure-Sensitive Adhesives on the in Vivo Performance of Membrane-Moderated Transdermal Therapeutic System of Nicardipine Hydrochloride in Human Volunteers","volume":"55","author":"Krishnaiah","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0378-5173(02)00401-5","article-title":"Influence of Limonene on the Bioavailability of Nicardipine Hydrochloride from Membrane-Moderated Transdermal Therapeutic Systems in Human Volunteers","volume":"247","author":"Krishnaiah","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/bdd.2510080205","article-title":"Single Intravenous Dose and Steady-state Oral Dose Pharmacokinetics of Nicardipine in Healthy Subjects","volume":"8","author":"Wagner","year":"1987","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00003088-198916010-00004","article-title":"Influence of Renal Function on the Pharmacokinetics and Cardiovascular Effects of Nisoldipine After Single and Multiple Dosing","volume":"16","author":"Burggraaf","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/clpt.1989.80","article-title":"Single- and Multiple-Dose Nisoldipine Kinetics and Effects in the Young, the Middle-Aged, and the Elderly","volume":"45","author":"Burggraaf","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002280050593","article-title":"The Effect of Ketoconazole on the Pharmacokinetics, Pharmacodynamics and Safety of Nisoldipine","volume":"55","author":"Heinig","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2125.1991.tb03916.x","article-title":"The Interactions between Nisoldipine and Two Beta-adrenoceptor Antagonists-atenolol and Propranolol","volume":"32","author":"Elliott","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/009127009203200614","article-title":"Multiple Dose Pharmacokinetics of Four Different Doses of Nisoldipine in Hypertensive Patients","volume":"32","author":"Chandler","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1994.83","article-title":"Pharmacokinetic and Pharmacodynamic Interactions during Multiple-Dose Administration of Nisoldipine and Propranolol","volume":"55","author":"Walker","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.1989.tb03420.x","article-title":"The Contribution of Nisoldipine-induced Changes in Liver Blood Flow to Its Pharmacokinetics after Oral Administration","volume":"27","author":"Burggraaf","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00265988","article-title":"The Pharmokinetics of Isradipine in Hypertensive Subjects","volume":"38","author":"Shenfield","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/j.1552-4604.1988.tb05717.x","article-title":"The Effects of Renal Function on the Disposition of Isradipine","volume":"28","author":"Chandler","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/bmc.2977","article-title":"Pharmacokinetic Properties of Isradipine after Single-dose and Multiple-dose Oral Administration in Chinese Volunteers: A Randomized, Open-label, Parallel-group Phase I Study","volume":"27","author":"Wang","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF00316480","article-title":"Effects of Diclofenac on Isradipine Pharmacokinetics and Platelet Aggregation in Volunteers","volume":"44","author":"Kovarik","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cpt.3499","article-title":"Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration","volume":"117","author":"Moser","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.1991.tb03908.x","article-title":"Differential Effects of Valproic Acid and Enzyme-inducing Anticonvulsants on Nimodipine Pharmacokinetics in Epileptic Patients","volume":"32","author":"Tartara","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/j.1552-4604.1994.tb02048.x","article-title":"Lack of a Pharmacokinetic\/Pharmacodynamic Interaction Between Nimodipine and Tirilazad Mesylate in Healthy Volunteers","volume":"34","author":"Fleishaker","year":"1994","journal-title":"J. Clin. Pharmacol."},{"key":"ref_248","first-page":"325","article-title":"Influence of the H2-Receptor Antagonists Cimetidine and Ranitidine on the Pharmacokinetics of Nimodipine in Healthy Volunteers","volume":"42","author":"Wingender","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_249","first-page":"293","article-title":"The Influence of Age on the Pharmacokinetics of Nimodipine","volume":"34","author":"Breuel","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1038\/sj.jhh.1001361","article-title":"Comparison of Two Nimodipine Formulations in Healthy Volunteers","volume":"16","author":"Coll","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10717540490280372","article-title":"Formulation and Evaluation of Limonene-Based Membrane-Moderated Transdermal Therapeutic System of Nimodipine","volume":"11","author":"Krishnaiah","year":"2004","journal-title":"Drug Deliv."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Kumar, A., D\u2019Andrea, C., Kohli, P., Kottayil, S.G., Longstreth, J., and Macdonald, R.L. (2025). Phase 1, Randomized, Crossover Study Comparing Intravenous GTX-104 to Oral Nimodipine in Healthy Human Subjects. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0323162"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00265956","article-title":"Investigation of Nimodipine Pharmacokinetics in Chinese Patients with Acute Subarachnoid Haemorrhage","volume":"45","author":"Kumana","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/clpt.1988.59","article-title":"Pharmacokinetics of Diltiazem in Patients with Unstable Angina Pectoris","volume":"43","author":"Hung","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/bdd.2510150305","article-title":"Pharmacokinetics and Pharmacodynamics of a Slow-release Formulation of Diltiazem after the Administration of a Single and Repeated Doses to Healthy Volunteers","volume":"15","author":"Lefebvre","year":"1994","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cpdd.107","article-title":"Pharmacokinetic Interactions between Topiramate and Diltiazem, Hydrochlorothiazide, or Propranolol","volume":"3","author":"Manitpisitkul","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0002-9149(82)80007-6","article-title":"The Pharmacokinetics of Diltiazem in Healthy American Men","volume":"49","author":"Zelis","year":"1982","journal-title":"Am. J. Cardiol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/j.1875-9114.1985.tb04451.x","article-title":"The Effect of Ranitidine and Cimetidine on Single-dose Diltiazem Pharmacokinetics","volume":"5","author":"Winship","year":"1985","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00613518","article-title":"Pharmacokinetics of Slow-Release Diltiazem and Its Effect on Atrioventricular Conduction in Healthy Volunteers","volume":"31","author":"Gordin","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/bdd.2510110206","article-title":"Influence of Food on the Bioavailability of Diltiazem and Two of Its Metabolites Following the Administration of Conventional Tablets and Slow-release Capsules","volume":"11","author":"Lery","year":"1990","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/bdd.2510120202","article-title":"Pharmacokinetics of Oral Diltiazem and Five of Its Metabolites in Patients with Chronic Renal Failure","volume":"12","author":"Tawashi","year":"1991","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF03189878","article-title":"Diltiazem Pharmacokinetics in Elderly Volunteers after Single and Multiple Doses","volume":"16","author":"Boucher","year":"1991","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/bdd.2510140903","article-title":"Comparative Pharmacokinetics and Pharmacodynamics of Two Marketed Bid Formulations of Diltiazem in Healthy Volunteers","volume":"14","author":"Guimont","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00045391-199408000-00005","article-title":"The Pharmacokinetics of Once-Daily Diltiazem Sr (Sustained-Release) in Young Versus Elderly Hypertensive Patients","volume":"1","author":"Argenti","year":"1994","journal-title":"Am. J. Ther."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00045391-199805000-00008","article-title":"Relative Bioavailability of Cardizem CD and Tiazac Controlled-Release Diltiazem Dosage Forms After Single and Multiple Dosing in Healthy Volunteers","volume":"5","author":"Dimmitt","year":"1998","journal-title":"Am. J. Ther."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1185\/03007999909115174","article-title":"Bioequivalence Assessment of Two Different Tablet Formulations of Diltiazem After Single and Repeated Doses in Healthy Subjects","volume":"15","author":"Loffreda","year":"1999","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1067\/mcp.2001.112513","article-title":"Pharmacokinetic Interaction between Single Oral Doses of Ditiazem and Sirolimus in Healthy Volunteers","volume":"69","author":"Bottiger","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1081\/DDC-100108372","article-title":"Comparative Bioavailability of Diltiazem in Prolonged-Release Oral Preparations","volume":"27","author":"Quiroga","year":"2001","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0091270003257214","article-title":"Pharmacokinetics of a Novel Diltiazem HCl Extended-Release Tablet Formulation for Evening Administration","volume":"43","author":"Sista","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jconrel.2003.12.026","article-title":"Evaluation of Novel Starch Acetate\u2013Diltiazem Controlled Release Tablets in Healthy Human Volunteers","volume":"95","author":"Korhonen","year":"2004","journal-title":"J. Control. Release"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0773.1992.tb00989.x","article-title":"Single-Dose and Steady-State Pharmacokinetics of Diltiazem Administered in Two Different Tablet Formulations","volume":"71","author":"Christrup","year":"1992","journal-title":"Pharmacol. Toxicol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1472-8206.1987.tb00546.x","article-title":"Effect of Size and Dosage Strength on the Biovailability of Two Diltiazem Formulations During Repeated Administrations in Humans","volume":"1","author":"Campistron","year":"1987","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0731-7085(90)80142-C","article-title":"Determination of Serum Diltiazem Concentrations in a Pharmacokinetic Study Using Gas Chromatography with Electron Capture Detection","volume":"8","year":"1990","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/00005344-199106000-00015","article-title":"Pharmacokinetic Properties and Antihypertensive Efficacy of Once-Daily Diltiazem","volume":"17","author":"Kelly","year":"1991","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00192556","article-title":"A Comparative Study of the Steady-State Pharmacokinetics of Immediate-Release and Controlled-Release Diltiazem Tablets","volume":"46","author":"Leeuwenkamp","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1099-081X(199601)17:1<43::AID-BDD935>3.0.CO;2-F","article-title":"The Relative Bioavailability of Two Marketed Controlled Release Diltiazem Dosage Forms at Steady State in Healthy Volunteers","volume":"17","author":"Lippert","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/j.1552-4604.1996.tb04171.x","article-title":"Pharmacokinetic Interactions of Moricizine and Diltiazem in Healthy Volunteers","volume":"36","author":"Shum","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/(SICI)1099-081X(199809)19:6<365::AID-BDD112>3.0.CO;2-R","article-title":"Steady-State Pharmacokinetics of Diltiazem and Hydrochlorothiazide Administered Alone and in Combination","volume":"19","author":"Weir","year":"1998","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1472-8206.1998.tb00986.x","article-title":"A Study Comparing Biopharmaceutic Characteristics of Four Once Daily Controlled Release Diltiazem Preparations","volume":"12","author":"Hendriks","year":"1998","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00045391-199907000-00006","article-title":"Steady-State Pharmacokinetics of High-Dose Diltiazem Hydrochloride (Cardizem CD) Administered Once Daily in Healthy Volunteers","volume":"6","author":"Giesing","year":"1999","journal-title":"Am. J. Ther."},{"key":"ref_281","first-page":"195","article-title":"Multicenter Studies on the Pharmacokinetic Profile of Sustained-Release Oral Diltiazem (300 mg) after Once a Day Repeated Administration: Influence of Age","volume":"34","author":"Bianchetti","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00228-007-0448-4","article-title":"The Effect on Heart Rate of Combining Single-Dose Fingolimod with Steady-State Atenolol or Diltiazem in Healthy Subjects","volume":"64","author":"Kovarik","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","article-title":"The Effect of Short- and Long-Term Administration of Verapamil on the Disposition of Cytochrome P450 3A and P-Glycoprotein Substrates","volume":"79","author":"Lemma","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9149(92)90363-4","article-title":"Impact of Food on the Pharmacokinetics and Electrocardiographic Effects of Sustained Release Verapamil in Normal Subjects","volume":"70","author":"Hoon","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jps.2600790310","article-title":"Influence of Food on the Bioavailability of a Sustained-Release Verapamil Preparation","volume":"79","author":"Conway","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03189707","article-title":"Pharmacokinetics of Sustained-Release Verapamil after a Single Administration and at Steady State","volume":"10","author":"Mattila","year":"1985","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00546708","article-title":"Inter- and Intra-Subject Variation in the First-Pass Elimination of Highly Cleared Drugs during Chronic Dosing","volume":"26","author":"Eichelbaum","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0895-7061(94)00162-5","article-title":"Combined Terazosin and Verapamil Therapy in Essential Hypertension: Hemodynamic and Pharmacokinetic Interactions","volume":"8","author":"Lenz","year":"1995","journal-title":"Am. J. Hypertens."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/clpt.1981.223","article-title":"Reduced Verapamil Clearance during Long-Term Oral Administration","volume":"30","author":"Shand","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1981.tb01854.x","article-title":"Pharmacokinetics, Bioavailability and ECG Response of Verapamil in Patients with Liver Cirrhosis","volume":"12","author":"Somogyi","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/1043-6618(91)90085-C","article-title":"The Influence of Age on the Pharmacokinetics of Verapamil","volume":"24","author":"Ahmed","year":"1991","journal-title":"Pharmacol. Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2125.1993.tb04202.x","article-title":"R-verapamil: Pharmacokinetics and Effects on PR Interval, Blood Pressure and Heart Rate","volume":"36","author":"Ahmed","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/clpt.1994.151","article-title":"Verapamil Stereoisomers during Racemic Verapamil Administration: Effects of Aging and Comparisons to Administration of Individual Stereoisomers","volume":"56","author":"Schwartz","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/j.1552-4604.1995.tb04031.x","article-title":"The Effect of Food, Time of Dosing, and Body Position on the Pharmacokinetics and Pharmacodynamics of Verapamil and Norverapamil","volume":"35","author":"Gupta","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2125.1998.00669.x","article-title":"Gut Wall Metabolism of Verapamil in Older People: Effects of Rifampicin-mediated Enzyme Induction","volume":"45","author":"Fromm","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s002280000189","article-title":"Effect of Grapefruit Juice on Pharmacokinetics and Pharmacodynamics of Verapamil Enantiomers in Healthy Volunteers","volume":"56","author":"Ho","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00228-002-0436-7","article-title":"Effects of Grapefruit Juice and Smoking on Verapamil Concentrations in Steady State","volume":"58","author":"Fuhr","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00045391-200007060-00002","article-title":"A Steady-State Evaluation of the Bioavailability of Chronotherapeutic Oral Drug Absorption System Verapamil PM After Nighttime Dosing Versus Immediate-Acting Verapamil Dosed Every Eight Hours","volume":"7","author":"Prisant","year":"2000","journal-title":"Am. J. Ther."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.clpt.6100208","article-title":"Cytochrome P450 3A5 Genotype Is Associated with Verapamil Response in Healthy Subjects","volume":"82","author":"Jin","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_300","first-page":"S24","article-title":"Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between Edoxaban Dose, Concentration, Anti-Factor Xa Activity, and Outcomes: An Analysis of Data from the Randomised, Double-Blind ENGAGE AF-TIMI 48 Trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjh.17899","article-title":"Assessment of Exposure to Direct Oral Anticoagulants in Elderly Hospitalised Patients","volume":"195","author":"Kampouraki","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-Analysis of Direct-Acting Oral Anticoagulants Compared with Warfarin in Patients >75 Years of Age","volume":"123","author":"Malik","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of Direct Oral Anticoagulants in Patients with Obesity for Treatment and Prevention of Venous Thromboembolism: Updated Communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jth.12149","article-title":"Measuring Oral Direct Inhibitors of Thrombin and Factor Xa: A Recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"11","author":"Baglin","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.108.025551","article-title":"In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans","volume":"37","author":"Lang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bcpt.12005","article-title":"Absence of Both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry","volume":"112","author":"Gong","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_311","unstructured":"European Medicines Agency (2026, June 22). Xarelto: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.110.033696","article-title":"Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity","volume":"38","author":"Ebner","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1941874415569069","article-title":"Dabigatran-Associated Intracranial Hemorrhage","volume":"5","author":"King","year":"2015","journal-title":"Neurohospitalist"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The Use of Dabigatran in Elderly Patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41397-024-00329-y","article-title":"Being Precise with Anticoagulation to Reduce Adverse Drug Reactions: Are We There Yet?","volume":"24","author":"Cross","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.acvd.2017.04.008","article-title":"Dosing Issues with Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Non-Valvular Atrial Fibrillation: Why We Should Not Underdose Our Patients","volume":"111","author":"Dillinger","year":"2018","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"e002340","DOI":"10.1136\/openhrt-2023-002340","article-title":"Correct Dosing, Adherence and Persistence of DOACs in Atrial Fibrillation and Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"10","author":"Emanuel","year":"2023","journal-title":"Open Heart"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the Clinical Response to Warfarin and Edoxaban: Findings from the Randomised, Double-Blind ENGAGE AF-TIMI 48 Trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/cts.12766","article-title":"Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients","volume":"13","author":"Konicki","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug\u2013Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults with Atrial Fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_327","unstructured":"World Heatlh Organization (2023). Global Report on Hypertension: The Race Against a Silent Killer, World Heatlh Organization."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/HYPERTENSIONAHA.121.17514","article-title":"Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations","volume":"78","author":"Bergland","year":"2021","journal-title":"Hypertension"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(19)31145-6","article-title":"Long-Term and Recent Trends in Hypertension Awareness, Treatment, and Control in 12 High-Income Countries: An Analysis of 123 Nationally Representative Surveys","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"e70140","DOI":"10.1002\/prp2.70140","article-title":"Pharmacokinetic Variability of Amlodipine Serum Concentration and Effect on Blood Pressure in Patients Treated for Hypertension","volume":"13","author":"Rognstad","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jch.14436","article-title":"Comparative Peripheral Edema for Dihydropyridines Calcium Channel Blockers Treatment: A Systematic Review and Network Meta-analysis","volume":"24","author":"Liang","year":"2022","journal-title":"J. Clin. Hypertens."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.3390\/cimb46070377","article-title":"The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations","volume":"46","author":"Jones","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-6175.2007.06504.x","article-title":"Pharmacologic and Therapeutic Considerations in Hypertension Therapy with Calcium Channel Blockers: Focus on Verapamil","volume":"9","author":"Sica","year":"2007","journal-title":"J. Clin. Hypertens."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"II-44","DOI":"10.1161\/01.HYP.11.3_Pt_2.II42","article-title":"Side Effects of Calcium Channel Blockers","volume":"11","author":"Russell","year":"1988","journal-title":"Hypertension"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1097\/00005344-198812007-00013","article-title":"Pharmacokinetics of Amlodipine in Renal Impairment","volume":"12","author":"Laher","year":"1988","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_336","unstructured":"Food and Drug Administration (2017). Norvasc (Amlodipine Besylate) Label. Highlights of Prescribing Information, Food and Drug Administration."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"113","DOI":"10.36011\/cpp.2023.5.e16","article-title":"Calcium Channel Blockers for Hypertension: Old, but Still Useful","volume":"5","author":"Lee","year":"2023","journal-title":"Cardiovasc. Prev. Pharmacother."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/0002-9343(92)90293-K","article-title":"Selecting Optimum Antihypertensive Therapy: Indications for Choosing a Calcium Channel Blocker","volume":"93","author":"Murphy","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_340","unstructured":"Sidhu, G., Patel, P., and Hashmi, M.F. (2024). Nisoldipine, StatPearls [Internet]."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10157-021-02153-1","article-title":"Calcium Channel Blocker in Patients with Chronic Kidney Disease","volume":"26","author":"Ohno","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1524-6175.2006.04482.x","article-title":"Calcium Channel Blocker Class Heterogeneity: Select Aspects of Pharmacokinetics and Pharmacodynamics","volume":"7","author":"Sica","year":"2005","journal-title":"J. Clin. Hypertens."},{"key":"ref_343","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, M., Barata, P., and Vale, N. (2026). From Population-Based PBPK to Individualized Virtual Twins: Clinical Validation and Applications in Medicine. J. Clin. Med., 15.","DOI":"10.3390\/jcm15031210"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:59:21Z","timestamp":1788339561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":343,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091103"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091103","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}